NextPharma to Manufacture Epigenomics' Colon Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NextPharma will manufacture Epigenomics' colon cancer test for certain markets worldwide, the firms announced today.

Under terms of the deal, NextPharma will manufacture Epigenomics' Epi proColon test kit in Europe and other markets and will manufacture a cGMP-compliant version of the test, which is currently under development, for the US market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.